Senekowitsch Stefan, Schick Philipp, Abrahamsson Bertil, Augustijns Patrick, Gießmann Thomas, Lennernäs Hans, Matthys Christophe, Marciani Luca, Pepin Xavier, Perkins Alan, Feldmüller Maximilian, Sulaiman Sarah, Weitschies Werner, Wilson Clive G, Corsetti Maura, Koziolek Mirko
Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, 17489 Greifswald, Germany.
Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, 431 83 Gothenburg, Sweden.
Pharmaceutics. 2022 Apr 6;14(4):801. doi: 10.3390/pharmaceutics14040801.
Drug absorption following oral administration is determined by complex and dynamic interactions between gastrointestinal (GI) physiology, the drug, and its formulation. Since many of these interactions are not fully understood, the COST action on "Understanding Gastrointestinal Absorption-related Processes (UNGAP)" was initiated in 2017, with the aim to improve the current comprehension of intestinal drug absorption and foster future developments in this field. In this regard, in vivo techniques used for the characterization of human GI physiology and the intraluminal behavior of orally administered dosage forms in the GI tract are fundamental to gaining deeper mechanistic understanding of the interplay between human GI physiology and drug product performance. In this review, the potential applications, advantages, and limitations of the most important in vivo techniques relevant to oral biopharmaceutics are presented from the perspectives of different research fields.
口服给药后的药物吸收取决于胃肠道(GI)生理学、药物及其制剂之间复杂而动态的相互作用。由于其中许多相互作用尚未完全明了,因此在2017年启动了关于“理解胃肠道吸收相关过程(UNGAP)”的欧洲科学与技术合作组织(COST)行动,旨在提高目前对肠道药物吸收的理解,并推动该领域的未来发展。在这方面,用于表征人体胃肠道生理学以及口服剂型在胃肠道内行为的体内技术,对于更深入地从机制上理解人体胃肠道生理学与药物产品性能之间的相互作用至关重要。在本综述中,从不同研究领域的角度介绍了与口服生物药剂学相关的最重要体内技术的潜在应用、优点和局限性。